The Melatonin Adjunct in the Acute myocaRdial Infarction Treated With Angioplasty (MARIA)
Background: Experimental studies have documented the beneficial effects of the endogenously produced antioxidant, melatonin, in reducing tissue damage and limiting cardiac pathophysiology in models of experimental ischemia-reperfusion. Melatonin confers cardioprotection against ischemia-reperfusion injury most likely through its direct free radical scavenging activities and its indirect actions in stimulating antioxidant enzymes. These actions of melatonin permit it to reduce molecular damage and limit infarct size in experimental models of transient ischemia and subsequent reperfusion.
Study design: The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial is an unicentric, prospective, randomized, double-blind, placebo-controlled, phase 2 study of the intravenous administration of melatonin. The primary efficacy end point of this study is to determine whether melatonin treatment reduces infarct size determined by the cumulative release of alpha-hydroxybutyrate dehydrogenase (area under the curve: 0 to 72 h). Other secondary end points will be the clinical events occurring within the first 90 days: death, sustained ventricular arrhythmias, resuscitation from cardiac arrest, cardiogenic shock, heart failure, major bleedings , stroke, need for revascularization, recurrent ischemia, re-infarctions and rehospitalization.
Implications: The MARIA trial tests a novel pharmacologic agent, melatonin, in patients with acute myocardial infarction and the hypothesis that it will confer cardioprotection against ischemia-reperfusion injury. If successful, the finding would support the use of melatonin in therapy of ischemic-reperfusion injury of the heart.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Unicentric, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Melatonin as an Adjunct in Patients With Acute myocaRdial Infarction Undergoing Primary Angioplasty|
- The primary efficacy end point in this study is to determine whether melatonin treatment reduces of infarct size as determined by the cumulative release of alpha-hydroxybutyrate dehydrogenase. [ Time Frame: within the first 72 hours ] [ Designated as safety issue: Yes ]
- Death, sustained ventricular arrhythmias, resuscitation from cardiac arrest, cardiogenic shock, heart failure, major bleedings, stroke, need for revascularization, recurrent ischemia, re-infarctions and re-hospitalization. [ Time Frame: within the first 90 days ] [ Designated as safety issue: Yes ]
|Study Start Date:||May 2013|
|Estimated Study Completion Date:||November 2015|
|Estimated Primary Completion Date:||November 2014 (Final data collection date for primary outcome measure)|
Patients will receive a total intravenous melatonin dose of 11.61 mg (approximately 166 microgram/kg) or placebo. The dose will be distributed in a volume of 500 ml of a isotonic and sterile solution of 100 microMolar melatonin during 150 minutes with a drip rate of 4.2 ml/min.
See article for more detailed description: Contemporary Clinical Trials 28 (2007) 532-539
Please refer to this study by its ClinicalTrials.gov identifier: NCT00640094
|Contact: Alberto Dominguez-Rodriguez, MD, PhD, FESC||+34 922 email@example.com|
|Hospital General Universitario Santa Lucia||Active, not recruiting|
|Cartagena, Murcia, Spain, 30202|
|University Hospital of Canarias||Recruiting|
|La Laguna, Tenerife, Spain, E-38320|
|Contact: Alberto Dominguez-Rodriguez, MD, PhD, FESC +34 922 679040 firstname.lastname@example.org|
|Sub-Investigator: Pedro Abreu-Gonzalez, PhD|
|Sub-Investigator: Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC.|
|Sub-Investigator: Russel J Reiter, PhD|
|Hospital Universitario Marqués de Valdecilla||Recruiting|
|Contact: José M. de la Torre Hernández, PhD email@example.com|
|Principal Investigator: José M. de la Torre Hernández, PhD|
|Principal Investigator:||Alberto Dominguez-Rodriguez, MD, PhD, FESC|